Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
11 p, 634.6 KB Diacerein : Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO / Pavelka, Karel (Institute of Rheumatology and Clinic of Rheumatology, Charles University) ; Bruyère, Olivier (Liège, Belgium) ; Cooper, Cyrus (Southampton, UK) ; Kanis, John A. (Sheffield, UK) ; Leeb, Burkhard F. (2nd Department of Medicine, State Hospital Stockerau, Centre for Rheumatology, Lower Austria, Karl Landsteiner Institute for Clinical Rheumatology, Stockerau, Austria) ; Maheu, Emmanuel (Rheumatology Department, AP-HP, St-Antoine Hospital) ; Martel-Pelletier, Johanne ; Monfort, Jordi (Hospital del Mar) ; Pelletier, Jean-Pierre (Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame-Hospital) ; Rizzoli, René (Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine) ; Reginster, Jean-Yves (Department of Public Health, Epidemiology and Health Economics, University of Liège) ; Universitat Autònoma de Barcelona. Departament de Medicina
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. [...]
2016 - 10.1007/s40266-016-0347-4
Drugs & Aging, Vol. 33 (february 2016) , p. 75-85  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.